DEEP BRAIN STIMULATION & VAGUS NERVE STIMULATION DEVICES | GLOBAL MARKETS

112 Pages | 44 Exhibits | 2018 Analysis | Forecasts Through 2022 Product Family: Market Reports




OVERVIEW:
This analysis includes a discussion of Deep Brain Stimulation (DBS) and Vagus Nerve Stimulation (VNS) devices, technological innovations, competitors, trends, and expected market growth. Market analysis includes 5-year market forecasts by segment and region, market drivers/limiters, estimated market share by region, and corporate strategies for success in the burgeoning market of neuromodulation.

DEEP BRAIN STIMULATION & VAGUS NERVE STIMULATION DEVICES MARKET HIGHLIGHTS

  • The DBS & VNS device segments contributed nearly one-quarter of the $4bn global neuromodulation market in 2017.
  • These segments were valued at more than $1bn in combined revenues in 2017 with expected growth of more than 10% over the next 5 years.
  • The US remains the largest market, accounting for nearly 65-85% of sales in 2017, although regions outside the US represent good growth potential.
  • The markets will be driven by the aging population at high risk of incurable, neurodegenerative diseases/disorders (such as Parkinson's disease/tremor and epilepsy), good US reimbursement for severe, drug-refractive patients, increasing adoption of DBS/VNS therapies by a skilled surgeon network, as well as fast-paced technological innovation creating safer, more precise neurostimulation that lessens debilitating symptoms, reduces side effects and improves quality of life.
Key Questions Answered
  • What is the value of the global DBS and VNS devices markets? What is the expected growth for each segment over the next 5 years?
  • What is the expected market growth by major region of the world (US, 5EU, Japan, and RoW)?
  • What are key drivers & limiters?
  • Technological innovations & trends? What are noninvasive brain stimulation technologies?
  • Who are the leading competitors, estimated market share by region, and strategic growth strategies? Emerging start-ups?


TABLE OF CONTENTS:
Executive Summary

i. Report overview
ii. Deep brain stimulation therapy for movement disorders
iii. Vagus nerve stimulation therapy for epilepsy 
iv. Prevalence of neurological diseases/disorders
v. Deep brain stimulation devices market 
vi. Vagus nerve stimulation devices market 
vii. Combined market
	a. Market drivers and limiters
	b. Technology trends
	c. Market share: deep brain stimulation 
	d. Market share: vagus nerve stimulation
viii. Methodology 
ix. Bibliography

Exhibit ES-1: Total neuromodulation devices market, estimated revenues by leading therapy segments, 2017
Exhibit ES-2: Prevalence of movement disorders, epilepsy and depression 
Exhibit ES-3: Deep brain stimulation devices, global market forecast ($m), 2017-22
Exhibit ES-4: Vagus nerve stimulation devices, global market forecast ($m), 2017-22
Exhibit ES-5: Combined deep brain stimulation and vagus nerve stimulation devices market, forecast sales By segment ($m), 2017-22 
Exhibit ES-6: Deep brain stimulation devices market, estimated global share by supplier, 2017
Exhibit ES-7: Vagus nerve stimulation devices market, estimated global share by supplier, 2017

1. Clinical Overview

1.1 Deep brain stimulation
1.2 Vagus nerve stimulation 
1.3 Movement disorders
	1.3.1 Parkinson's disease
	1.3.2 Essential tremor
	1.3.3 Dystonia
1.4 Epilepsy
1.5 Major depressive disorder
1.6 Prevalence of neurological disorders
1.7 Bibliography 

Exhibit 1-1: Diagram of Medtronic's deep brain stimulation system implantation 
Exhibit 1-2: Diagram of vagus nerve stimulation therapy 
Exhibit 1-3: Prevalence of movement disorders, epilepsy and depression

2. Deep Brain Stimulation Technology
 
2.1 Selected products 
	2.1.1 Abbott (St. Jude Medical) 
	2.1.2 Boston Scientific
	2.1.3 Medtronic 
2.2 Emerging competition
	2.2.1 Aleva Neurotherapeutics/Nuvectra
	2.2.2 Cala Health
	2.2.3 Nuvectra
	2.2.4 Saluda Medical
2.3 Risks 
2.4 Bibliography 

Exhibit 2-1: Implantable deep brain stimulation systems for movement disorders
Exhibit 2-2: Abbott's Infinity DBS system with proprietary directional leads
Exhibit 2-3: Boston Scientific's Vercise DBS System 
Exhibit 2-4: Medtronic DBS therapy indications
Exhibit 2-5: Medtronic's Activa DBS systems
Exhibit 2-6: Medtronic's Activa Patient Programmer and Recharger System
Exhibit 2-7: Nuvectra's Algovita SCS system
Exhibit 2-8: Saluda Medical's innovative closed-loop Evoke SCS System

3. Vagus Nerve Stimulation Technology

3.1 Selected products 
	3.1.1 LivaNova
	3.1.2 Medtronic 
	3.1.3 NeuroPace
3.2 Bibliography 

Exhibit 3-1: Vagus nerve stimulation using implantable VNS Therapy
Exhibit 3-2: Neuromodulation systems for the treatment of epilepsy
Exhibit 3-3: LivaNova's newest VNS Therapy System, the SenTiva 
Exhibit 3-4: The anterior nucleus of the thalamus
Exhibit 3-5: NeuroPace's new RNS System, including new RNS Tablet

4. Noninvasive Brain Stimulation Technology
 
4.1 Selected products 
	4.1.1 Brainsway
	4.1.2 Cerevast Medical 
	4.1.3 Fisher Wallace
	4.1.4 Magstim 
	4.1.5 MagVenture 
	4.1.6 Neuronetics
	4.1.7 NeuroSigma
	4.1.8 Nexstim
4.2 Bibliography 

Exhibit 4-1: Selected noninvasive brain stimulation systems
Exhibit 4-2: Brainsway Deep TMS system
Exhibit 4-3: Cerevast Medical's Neuros pulsed transdermal electrical stimulation system
Exhibit 4-4: The Fisher Wallace stimulator for home use
Exhibit 4-5: The Magstim Horizon Performance TMS system 
Exhibit 4-6: The MagVenture TMS Therapy system for treatment of depression
Exhibit 4-7: Image displaying a reduction of brain activity in depression 
Exhibit 4-8: Neuronetic's NeuroStar Advanced Therapy System 
Exhibit 4-9: The Nexstim NBT System

5. Market Analysis
 
5.1 Deep brain stimulation devices market
	5.1.1 Market forecast: global
	5.1.2 Market forecast: by region 
	5.1.3 Market drivers and limiters 
	5.1.4 Market share: global
	5.1.5 Market share: by region
5.2 Vagus nerve stimulation devices market
	5.2.1 Market forecast: global
	5.2.2 Market forecast: by region 
	5.2.3 Market drivers and limiters 
	5.2.4 Market share: global
	5.2.5 Market share: by region
5.3 Combined market 
5.4 Corporate profiles
	5.4.1 Abbott
	5.4.2 Boston Scientific
	5.4.3 LivaNova
	5.4.4 Medtronic 
	5.4.5 Nuvectra
5.5 Bibliography 

Exhibit 5-1: Total neuromodulation devices market, estimated revenues by leading therapy segments, 2017
Exhibit 5-2: Deep brain stimulation devices, global market forecast ($m), 2017-22
Exhibit 5-3: Deep brain stimulation devices market, estimated share of revenues by region, 2017
Exhibit 5-4: Deep brain stimulation devices market, forecast sales by region ($m), 2017-22
Exhibit 5-5: Deep brain stimulation devices market, estimated global share by supplier, 2017 
Exhibit 5-6: Deep brain stimulation devices market ($m), estimated share by supplier and region, 2017 
Exhibit 5-7: Vagus nerve stimulation devices, global market forecast ($m), 2017-22
Exhibit 5-8: Vagus nerve neurostimulation devices, estimated share of revenues by region, 2017 
Exhibit 5-9: Vagus nerve stimulation devices, forecast sales by region ($m), 2017-22 
Exhibit 5-10: Vagus nerve stimulation devices market, estimated global share by supplier, 2017 
Exhibit 5-11: Vagus nerve stimulation devices market, estimated share by supplier and region, 2017
Exhibit 5-12: Combined deep brain stimulation and vagus nerve stimulation devices market, forecast sales by segment ($m), 2017-22 

Appendix A: company listing


COMPANIES COVERED:

  1. Abbott Laboratories
  2. Aleva Neurotherapeutics
  3. Boston Scientific
  4. Brainsway
  5. Cala Health
  6. Cerevast Medical
  7. Fisher Wallace
  8. Insightec
  9. LivaNova
  10. Magventure A/S
  11. Magstim Co. Ltd.
  12. Medtronic plc
  13. Neuronetics
  14. NeuroPace
  15. NeuroSigma
  16. Nexstim
  17. Nuvectra Corporation
  18. Saluda Medical
  19. Thync Global
Contact Us

Need help finding medtech research? Let us help you!